Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine

Résumé fourni par la source

Vaccination is an effective population strategy for preventing severe COVID-19 disease and reducing infection transmission.1 The emergence of new variants, particularly more transmissible strains, such as the omicron variants, has resulted in high infection rates in unvaccinated and vaccinated individuals.2 Concerns about more transmissible variants are especially pertinent for immunosuppressed individuals, in whom vaccines are less immunogenic and less effective.3 We and others have shown that patients with inflammatory bowel disease (IBD) established on immunosuppressive drugs, including infliximab (an anti–tumor necrosis factor [TNF] monoclonal antibody) or tofacitinib (a pan–Janus kinase [JAK]-inhibitor), have reduced vaccine-induced humoral responses after 2 and 3 doses of COVID-19 vaccination.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.